Use of Diagnostic Measures in Chronic Obstructive Pulmonary Disease (COPD) in Routine Practice and Their Impact on Treatment Decisions

Completed

• Conditions: Pulmonary Disease, Chronic Obstructive
• Interventions: Other: Doctor's questionnaire; Other: Subject file

• Registration Number: NCT03465332
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This study will evaluate the diagnostic measures (including blood eosinophil counts) commonly used by lung specialist's in routine clinical care of subjects with COPD in Germany and how these diagnostic tests influence the physician's treatment decisions. The study will be conducted in three parts. In the first part, lung specialist's, who will not participate in the survey, will develop doctor's questionnaire. The second part is an interventional cross-sectional study, wherein approximately 30 lung specialists will be enrolled and data on their perspective on diagnosis and treatment of COPD subjects will be collected via the revised doctor's questionnaire. The third part is a retrospective non-interventional study where each doctor will collect retrospective data from selected subjects with COPD from the time of informed consent up to 12 months before. The retrospective data will be collected from subject files of approximately 250 subjects with COPD.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-03-08
• Study First Submitted QC: 2018-03-08
• Study First Posted: 2018-03-14
• Study Start: 2018-04-19
• Primary Completion: 2018-08-30
• Study Completion: 2018-08-30
• Status Verified: 2019-01
• Last Update Submitted: 2019-01-11
• Last Update Posted: 2019-01-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 251

Inclusion Criteria

For participating centers (Sample 1: 30 lung specialists from Germany)

• More than 10 years of experience in respiratory medicine
• At least 500 subjects under supervision in hospital- or office-based setting: a) Focus on obstructive lung diseases. b) Board certification. c) Informed consent to participate in this study and to share files of consenting subjects.

For subjects (Sample 2: 250 COPD subjects from these 30 doctors from sample 1)

• Written informed consent to use his/her data.
• Age >=40 years
• Pack years >10, current or former smoking
• Duration of COPD: >=1 year since COPD diagnosis record in subject files (also confirmed by spirometry)
• No concurrent asthma diagnosis
• At least one year of documented disease history at participating study doctors and have to be under the care of the before mentioned physician during this time because of COPD.

Read More

Exclusion Criteria

• Subjects who are pregnant and breastfeeding (in the last 12 months)
• Subjects currently participating in any interventional study
• Subjects with severe comorbidities which would have influence on the COPD therapy

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Lung specialist	Doctor's questionnaire	Approximately 30 lung specialists in Germany with a sufficient number of COPD subjects under supervision will be enrolled in the study to document physician's attitudes on COPD diagnosis and therapy, and to document data on about 250 subjects with COPD.
Subjects with COPD	Subject file	Data from approximately 250 subjects with COPD under supervision of lung specialists enrolled in the study will be analyzed.

Primary Outcome Measures

Name	Time	Method
Number of physician reported rationale for choice of diagnostic test	Up to 12 months	The reasons for choice of diagnostic test will be determined from doctor's questionnaires and from medical chart review.
Number of physicians with usage of diagnostic tests in routine clinical practice	Up to 12 months	The data on diagnostic test including blood eosinophil count commonly used by lung specialists in routine clinical practice will be obtained from doctor's questionnaire.

Secondary Outcome Measures

Name	Time	Method
Number of physician reported reasons for drug selection	Up to 12 months	The selection of drugs by lung specialists for subjects with COPD will be analyzed using information obtained from medical chart review.
Number of subjects with use of patient reported outcome (PRO) assessment	Up to 12 months	Number of subjects with use of questionnaires like COPD assessment test (CAT) and dyspnea assessment will be analyzed using data from subject files.
Number of subjects with concomitant diseases	Up to 12 months	Number of subjects with concomitant diseases will be analyzed using data from subject files.
Number of subjects with a history of respiratory medication	Up to 12 months	Number of subjects with a history of respiratory medication will be analyzed using data from subject files.
Number of subjects receiving immunosuppressive treatment	Up to 12 months	Number of subjects receiving immunosuppressive treatment will be analyzed using data from subject files.
Number of subjects receiving oral corticosteroids (OCS) for exacerbations	Up to 12 months	Number of subjects with maintenance and rescue use of OCS for exacerbations will be analyzed using data from subject files.
Number of subjects receiving allergic treatment	Up to 12 months	Number of subjects receiving allergic treatment will be analyzed using data from subject files.
Number of subjects receiving any COPD medication	Up to 12 months	Number of subjects receiving any COPD medication will be analyzed using data from subject files.
Number of subjects with emergency room visits related to COPD	Up to 12 months	Number of subjects with emergency room visits related to COPD will be analyzed using data from subject files.
Number of physician reported reasons for blood eosinophil test selection	Up to 12 months	The reasons blood eosinophil test selection will be analyzed using data from doctor's questionnaires.
Number of subjects receiving COPD maintenance treatment	Up to 12 months	Number of subjects receiving COPD maintenance treatment will be analyzed using data from subject files.
Number of subjects with hospitalization for COPD	Up to 12 months	Number of subjects with hospitalization for COPD will be analyzed using data from subject files.
Number of subjects with use of other diagnostic measures	Up to 12 months	Number of subjects with use of other diagnostic measures such as spirometry, X-ray, thoracic computer tomography and specific blood tests will be analyzed using data from subject files.
Number of subjects receiving current medication	Up to 12 months	Number of subjects receiving current medication will be analyzed using data from subject files.
Number of subjects with use of antibiotics	Up to 12 months	Number of subjects with use of antibiotics will be analyzed using data from subject files.
Number of subjects with history of exacerbations	Up to 12 months	Number of subjects with history of exacerbations will be analyzed using data from subject files.

Trial Locations

Locations (1)

GSK Investigational Site; 🇩🇪 Berlin, Germany